Madhav V. Dhodapkar, MBBS

Arthur H. Bunker and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology; Chief, Section of Hematology, Department of Internal Medicine; Clinical Research Program Leader, Hematology Program, Yale Cancer Center

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Hematology Program


National Gaucher Disease Treatment Center

Yale Medical Group

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (1994)

  • Medical Oncology AB of Internal Medicine (1995)

Clinical Trials

Conditions Study Title
Multiple Myeloma Study of High-dose Influenza Vaccine Efficacy by Repeated dosing IN Gammopathy patients: A 2 Arm randomized study (SHIVERING 2 Trial)
Multiple Myeloma A Phase 1b Study of the Safety and Pharmacokinetics of MPDL3280A (Anti-PD-L1 Antibody) Alone or in Combination with Lenalidomide in Patients with Multiple Myeloma (Relapsed and Post-Autologous Stem Cell Transplantation)
Multiple Myeloma A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Myeloid and Monocytic Leukemia A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Multiple Myeloma Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Multiple Myeloma S1304, A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Myeloid and Monocytic Leukemia A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Leukemia, other A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Myeloid and Monocytic Leukemia E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, other (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Multiple Myeloma Immunology and Pathobiology of Plasma Cell Disorders
Unknown Sites Study of Immune System in Patients with Cancer and Blood Disorders
Bones and Joints Correlation Between Macrophage Fusion and Severity of GVHD

Edit this profile

Contact Info

Madhav V. Dhodapkar, MBBS
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavillion 7

New Haven, CT 06510
Mailing Address
PO Box 208028
333 Cedar Street, TMP 3

New Haven, CT 06520-8028